Micromet to Report Third Quarter 2011 Financial Results on November 8

ROCKVILLE, Md.--(BUSINESS WIRE)-- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that it will host a conference call and audio webcast to review its third quarter 2011 financial results on Tuesday, November 8, 2011, at 8:30 AM ET.

To participate in the conference call, please dial 866-788-0540 (domestic) or 857-350-1678 (international) and reference the access code 68459017. The presentation will be available via webcast in the Investors and Media section of the Micromet website at www.micromet.com.

A replay of the call will be available from 11:30 AM ET on November 8, 2011 until midnight ET on November 15, 2011. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 24160187. The archived webcast will be available for 30 days at www.micromet.com.

About Micromet, Inc.

Micromet is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. The Company is advancing a robust pipeline of novel therapeutics based on its proprietary BiTE® technology. The Company's lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Amgen, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, MedImmune, Nycomed and Sanofi. For additional information, please visit www.micromet.com



CONTACT:

Micromet, Inc.
Jennifer Neiman
Director, Corporate Communications
240-235-0246
[email protected]

KEYWORDS:   United States  North America  Maryland

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Finance  Research  Science

MEDIA:

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.